PARQuit Smoking Cessation Intervention for Adults With Serious Mental Illness
NCT ID: NCT03950427
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
131 participants
INTERVENTIONAL
2019-07-08
2025-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
NCT05030272
Mobile App for Smoking Cessation and Mental Health
NCT04887558
Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness
NCT02845440
Smoking Cessation Intervention: Effectiveness in Primary Care
NCT00296647
Helping Veterans With SMI "StayQuit" From Smoking After Inpatient Hospitalization
NCT03367520
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study participants will receive counseling to quit smoking and a medication to help decrease cravings and withdrawal. Additionally, participants will be randomly selected to participate in either a game-based physical activity group or a game group where the participants sit to play the games.
Participants will be in this study for 12 weeks total. There are 3 assessment visits (2 hours each) at the beginning of the study, 6 weeks after starting, and at the end of the 12 weeks. There will be 8 30- minute counseling sessions during the 12 weeks. The hour-long videogame groups will be held 3 times a week for 12 weeks (36 sessions). Upon completion of the 12-week program, there will be a 1-2 hour group interview. The total time commitment is 48 hours over the course of the 12-week study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Game-based Physical Activity Group
The game-based physical activity group, will play active games using the Kinect for Xbox 360 game system or outdoors in a public park. Each game group will be facilitated by the study coordinator, the principal investigator or other study staff.
Participants in this group will also receive bupropion and counseling for smoking cessation.
Videogame-based physical activity
videogame-based physical activity
Bupropion
Bupropion
Counseling
Counseling for smoking cessation
Sedentary Videogame Group
The sedentary videogame group will play games while seated using the Xbox 360 game system (without the Kinect sensor) or seated outdoors in a public park. Each sedentary videogame group will be facilitated by study staff.
Participants in this group will also receive bupropion and counseling for smoking cessation.
Sedentary videogame
sedentary videogame
Bupropion
Bupropion
Counseling
Counseling for smoking cessation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Videogame-based physical activity
videogame-based physical activity
Sedentary videogame
sedentary videogame
Bupropion
Bupropion
Counseling
Counseling for smoking cessation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years and older
* Smoking at least five cigarettes per day for the past 6 months
* Willingness to set a quit date
* Not currently taking bupropion or using nicotine replacement therapy (NRT)
* Current participant in the residential or day treatment program at a Progress Foundation program with the intention to continue in the residential or day treatment program for at least the 12 week intervention period
* Capacity to consent.
* SMI is characterized by the American Psychological Association as distinct conditions that require routine management, produce functional impairment, and interfere with quality of life. Individuals that typically meet the criteria of SMI have illnesses that include schizophrenia, schizoaffective disorder, psychotic disorders, major depressive disorders, bipolar disorders, and borderline personality disorder.
Exclusion Criteria
* Diagnosis of seizure disorder, history of anorexia/bulimia, undergoing abrupt discontinuation of ethanol or sedatives, other conditions that increase seizure risk (e.g., arteriovenous malformation (AVM), severe head injury, central nervous system (CNS) tumor)
* use of Monoamine oxidase (MAO) inhibitors (concurrently or within 14 days of discontinuing either bupropion or the MAO inhibitor)
* Planning to become pregnant during the study period
* Previous participation in the videogame-based physical activity intervention.
* Known medical conditions or other physical problems that need special attention in an exercise program (e.g. prior myocardial infarction, uncontrolled hypertension, history of angioplasty, history of angina, use of nitroglycerin to treat angina)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tobacco Related Disease Research Program
OTHER
University of California, San Francisco
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heather Leutwyler, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Francisco
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22637
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2022-02281
Identifier Type: REGISTRY
Identifier Source: secondary_id
T29IP0235
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.